{
    "initial_scores": {
        "ideological_tilt": 0,
        "immigration": 0,
        "executive_power": 1,
        "federalism": 0,
        "security_liberty": 2,
        "economic_regulation": 0,
        "social_inclusion": 0
    },
    "critique": "This executive order outlines the policy and procedures for administering investigational drugs to military personnel, including the circumstances under which informed consent can be waived. It balances the need to protect military personnel from health threats with the ethical considerations of informed consent. The order emphasizes the role of the Secretary of Defense, the President, and the FDA in the decision-making process. It also includes provisions for training, monitoring, and public notice. The order does not directly address immigration, economic regulation, or social inclusion. It touches on national security and civil liberties by addressing the waiver of informed consent. It could be argued that it expands executive power by allowing the President to waive informed consent, but this is balanced by the requirements for justification and consultation with other agencies. The order seems ideologically neutral, focusing on practical considerations of military health and safety.",
    "revised_scores": {
        "ideological_tilt": 0,
        "immigration": 0,
        "executive_power": 1,
        "federalism": 0,
        "security_liberty": 2,
        "economic_regulation": 0,
        "social_inclusion": 0
    }
}